Detalhe da pesquisa
1.
Fibroblast growth factor receptor 3 overexpression mediates ALK inhibitor resistance in ALK-rearranged non-small cell lung cancer.
Cancer Sci
; 113(11): 3888-3900, 2022 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-35950895
2.
Drug resistance mechanisms in Japanese anaplastic lymphoma kinase-positive non-small cell lung cancer and the clinical responses based on the resistant mechanisms.
Cancer Sci
; 111(3): 932-939, 2020 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-31961053
3.
GSK3 inhibition circumvents and overcomes acquired lorlatinib resistance in ALK-rearranged non-small-cell lung cancer.
NPJ Precis Oncol
; 6(1): 16, 2022 Mar 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-35301419
4.
Prevention of hematogenous metastasis by neutralizing mice and its chimeric anti-Aggrus/podoplanin antibodies.
Cancer Sci
; 102(11): 2051-7, 2011 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-21824222
5.
Platelet-derived lysophosphatidic acid mediated LPAR1 activation as a therapeutic target for osteosarcoma metastasis.
Oncogene
; 40(36): 5548-5558, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34302117
6.
Microsecond-timescale MD simulation of EGFR minor mutation predicts the structural flexibility of EGFR kinase core that reflects EGFR inhibitor sensitivity.
NPJ Precis Oncol
; 5(1): 32, 2021 Apr 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-33863983
7.
PRMT5, a novel TRAIL receptor-binding protein, inhibits TRAIL-induced apoptosis via nuclear factor-kappaB activation.
Mol Cancer Res
; 7(4): 557-69, 2009 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-19372584
8.
AP-1-Dependent miR-21 expression contributes to chemoresistance in cancer stem cell-like SP cells.
Oncol Res
; 19(1): 23-33, 2010.
Artigo
em Inglês
| MEDLINE | ID: mdl-21141738
9.
Dofequidar fumarate sensitizes cancer stem-like side population cells to chemotherapeutic drugs by inhibiting ABCG2/BCRP-mediated drug export.
Cancer Sci
; 100(11): 2060-8, 2009 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-19673889
10.
Prediction of ALK mutations mediating ALK-TKIs resistance and drug re-purposing to overcome the resistance.
EBioMedicine
; 41: 105-119, 2019 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-30662002
11.
The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models.
Nat Commun
; 10(1): 3604, 2019 08 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-31399568
12.
Recurrent 8q24 rearrangement in blastic plasmacytoid dendritic cell neoplasm: association with immunoblastoid cytomorphology, MYC expression, and drug response.
Leukemia
; 32(12): 2590-2603, 2018 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-29795241
13.
P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer.
EBioMedicine
; 3: 54-66, 2016 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-26870817
14.
Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer.
Clin Cancer Res
; 21(1): 166-74, 2015 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-25351743
15.
Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib.
Clin Cancer Res
; 20(22): 5686-96, 2014 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-25228534
16.
Platelets promote tumor growth and metastasis via direct interaction between Aggrus/podoplanin and CLEC-2.
PLoS One
; 8(8): e73609, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-23991201